TACR1 and lung cancer: Inhalable nanocarrier formulations for lung cancer tested on A549 lung cancer cells showed enhanced cytotoxicity, improved permeability, high cellular uptake, NK-1 receptor inhibition, and favorable biodistribution to lungs after intratracheal administration.